 Complement C3d
"Complement C3d" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 302-amino-acid fragment in the alpha chain (672-1663) of C3b. It is generated when C3b is inactivated (iC3b) and its alpha chain is cleaved by COMPLEMENT FACTOR I into C3c, and C3dg (955-1303) in the presence COMPLEMENT FACTOR H. Serum proteases further degrade C3dg into C3d (1002-1303) and C3g (955-1001).
| Descriptor ID |
D015933
|
| MeSH Number(s) |
D12.776.124.486.274.250.260.750
|
| Concept/Terms |
Complement C3d- Complement C3d
- C3d, Complement
- Complement Component 3d
- Component 3d, Complement
- Complement C3d Fragment
- C3d Fragment, Complement
- Fragment, Complement C3d
- C3d Complement
- Complement, C3d
- Complement 3d
|
Below are MeSH descriptors whose meaning is more general than "Complement C3d".
Below are MeSH descriptors whose meaning is more specific than "Complement C3d".
This graph shows the total number of publications written about "Complement C3d" by people in this website by year, and whether "Complement C3d" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 | | 2001 | 2 | 0 | 2 | | 2002 | 1 | 0 | 1 | | 2005 | 3 | 1 | 4 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2008 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2010 | 2 | 1 | 3 | | 2011 | 1 | 1 | 2 | | 2012 | 1 | 0 | 1 | | 2013 | 1 | 0 | 1 | | 2016 | 1 | 2 | 3 | | 2017 | 1 | 1 | 2 | | 2019 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Complement C3d" by people in Profiles.
-
Renner B, Poppelaars F, Laskowski J, Serkova NJ, Kulik L, Holers VM, Thurman JM. Noninvasive Detection of iC3b/C3d Deposits in the Kidney Using a Novel Bioluminescent Imaging Probe. J Am Soc Nephrol. 2023 07 01; 34(7):1151-1154.
-
Wahid AA, Dunphy RW, Macpherson A, Gibson BG, Kulik L, Whale K, Back C, Hallam TM, Alkhawaja B, Martin RL, Meschede I, Laabei M, Lawson ADG, Holers VM, Watts AG, Crennell SJ, Harris CL, Marchbank KJ, van den Elsen JMH. Insights Into the Structure-Function Relationships of Dimeric C3d Fragments. Front Immunol. 2021; 12:714055.
-
Kulik L, Laskowski J, Renner B, Woolaver R, Zhang L, Lyubchenko T, You Z, Thurman JM, Holers VM. Targeting the Immune Complex-Bound Complement C3d Ligand as a Novel Therapy for Lupus. J Immunol. 2019 12 15; 203(12):3136-3147.
-
Kwak JW, Laskowski J, Li HY, McSharry MV, Sippel TR, Bullock BL, Johnson AM, Poczobutt JM, Neuwelt AJ, Malkoski SP, Weiser-Evans MC, Lambris JD, Clambey ET, Thurman JM, Nemenoff RA. Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. Cancer Res. 2018 01 01; 78(1):143-156.
-
He YG, Pappworth IY, Rossbach A, Paulin J, Mavimba T, Hayes C, Kulik L, Holers VM, Knight AM, Marchbank KJ. A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice. Immunobiology. 2018 01; 223(1):125-134.
-
Hempel JC, Poppelaars F, Gaya da Costa M, Franssen CF, de Vlaam TP, Daha MR, Berger SP, Seelen MA, Gaillard CA. Distinct in vitro Complement Activation by Various Intravenous Iron Preparations. Am J Nephrol. 2017; 45(1):49-59.
-
Hannan JP, Laskowski J, Thurman JM, Hageman GS, Holers VM. Mapping the Complement Factor H-Related Protein 1 (CFHR1):C3b/C3d Interactions. PLoS One. 2016; 11(11):e0166200.
-
Poppelaars F, Gaya da Costa M, Berger SP, Assa S, Meter-Arkema AH, Daha MR, van Son WJ, Franssen CF, Seelen MA. Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients. J Transl Med. 2016 08 05; 14(1):236.
-
Thurman JM, Kulik L, Orth H, Wong M, Renner B, Sargsyan SA, Mitchell LM, Hourcade DE, Hannan JP, Kovacs JM, Coughlin B, Woodell AS, Pickering MC, Rohrer B, Holers VM. Detection of complement activation using monoclonal antibodies against C3d. J Clin Invest. 2013 May; 123(5):2218-30.
-
Li K, Gor J, Holers VM, Storek MJ, Perkins SJ. Solution structure of TT30, a novel complement therapeutic agent, provides insight into its joint binding to complement C3b and C3d. J Mol Biol. 2012 May 04; 418(3-4):248-63.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|